

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCABRBEV

Page 1 of 2

DOCTOR'S	ORDERS	Ht	cm	Wt	kg BSA		m²
REMINDER: Ple	ase ensure drug aller	gies and previous	bleomyci	n are	documented on the	Allergy &	Alert Form
DATE:		To be given:			Cycle #:		
Date of Previous	Cycle:						
	ent week(s) vlatelets day of treatme	ent					
May proceed with doses as written, if within 72 hours ANC <u>greater than or equal to</u> 1.5 x 10 ⁹ /L, Platelets <u>greater than or equal to</u> 100 x 10 ⁹ /L, BP <u>less than or equal to</u> 150/100 mmHg. For patients on warfarin, hold bevacizumab if INR <u>greater than</u> 3.0							
Dose modification Proceed with tre	for: Hematolog	gy	Γoxicity _				
PREMEDICATI	ONS: Patient to take	own supply. RN/Pha	armacist to	o conf	irm		·
dexamethasone 8 mg or 12 mg (circle one) PO 30 to 60 minutes prior to CARBOplatin ondansetron 8 mg PO 30 to 60 minutes prior to CARBOplatin Other:							
** Have Hypersensitivity Reaction Medications and Protocol Available**							
CHEMOTHERAPY:							
PACLitaxel NAB (ABRAXANE) 260 mg/m² x BSA =mg Dose Modification:% =mg IV over 30 minutes (in empty sterile PVC, non-PVC or non-DEHP bag and tubing; use tubing with 15 micron filter)							
☐ Dose Modif	IC 6 or 5 (circle one) of the first one	mg	n	ng			
Blood pressure measurement pre-bevacizumab dose.							
	s mg/kg x kg = S over 15 minutes (first		·).				
bevacizumab 15 mg/kg x kg = mg							
IV in 100 to 250 mL NS over 30 minutes (first infusion over 1 hour).							
Blood pressure m	easurement post-beva	cizumab infusion for	first 3 cyc	eles.			
·	elect bevacizumab brand		•		cy III-190		
Drug	Brand (Pharmacist to	complete. Please pri	int.)	Ph	Pharmacist Initial and Date		
bevacizumab							
DOCTOR'S SIGNATURE: SIGNATURE:							JRE:
						UC:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOCABRBEV

Page 2 of 2

DOCTOR'S ORDERS						
DATE:						
RETURN APPOINTMENT ORDERS						
Return in <u>three</u> weeks for Doctor and Cycle						
Last Treatment. Return in week(s).						
CBC & Diff, platelets, creatinine, laboratory urinalysis or urine dipstick for protein prior to next cycle.						
☐ CBC & Diff, platelets on Day 14.						
☐ 24 h urine for total protein within 3 days prior to next bevacizumab dose if 2+ or 3+ dipstick or greater than or equal to 1 g/L laboratory urinalysis for protein						
☐ INR weekly ☐ INR prior to next cycle						
Prior to next cycle, if clinically indicated:						
☐ Bilirubin ☐ Alk Phos ☐ GGT ☐ ALT ☐ LDH						
☐ Tot Prot ☐ Albumin ☐ CA 15-3 ☐ CA 125 ☐ CA 19-9 ☐ CEA ☐ SCC						
☐ Refer to Hereditary Cancer Program (see accompanying referral form)						
Other tests:						
☐ Consults:						
\square See general orders sheet for additional requests.						
DOCTOR'S SIGNATURE:	SIGNATURE:					
	nc:					